Get the Stockscreener App
0.421
0.00%
0.00
Silo Pharma Inc stock is traded at $0.421, with a volume of 138.87K.
It is up +0.00% in the last 24 hours and down -20.60% over the past month.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
See More
Previous Close:
$0.421
Open:
$0.43
24h Volume:
138.87K
Relative Volume:
0.03
Market Cap:
$6.96M
Revenue:
$72,100
Net Income/Loss:
$-4.23M
P/E Ratio:
-0.6936
EPS:
-0.607
Net Cash Flow:
$-4.66M
1W Performance:
-4.77%
1M Performance:
-20.60%
6M Performance:
-8.97%
1Y Performance:
-48.02%
1-Day Range:
$0.415
$0.44
1-Week Range:
$0.415
$0.48
52-Week Range:
$0.221
$1.1299
Silo Pharma Inc Stock (SILO) Company Profile
Name
Silo Pharma Inc
Sector
Industry
Phone
(718) 400-9031
Address
677 N. WASHINGTON BLVD, SARASOTA
Compare SILO vs MOBBW, GOODO, SHMD, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SILO
SILO PHARMA INC
|
1.71 | 17.96M | 0 | 0 | 0 | 0.00 |
MOBBW
Mobilicom Limited Warrants
|
2.15 | 3.21B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
20.39 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
5.60 | 323.68M | 52.15M | -21.46M | 0 | -0.4675 |
PSNYW
Polestar Automotive Holding Uk
|
3.0501 | 299.25M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.97 | 0 | 0 | 0 | 0 | 0.00 |
Silo Pharma Inc Stock (SILO) Latest News
Silo Pharma files patent for ibogaine-based TBI treatment By Investing.com - Investing.com Canada
With no FDA-approved TBI drugs, Silo pursues ibogaine therapy - Stock Titan
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury - GlobeNewswire
Silo Pharma rallies after securing key patent allowance - MSN
SILO Silo Pharma reports wider-than-expected Q4 2023 loss, shares dip 1.62% amid weak investor sentiment.Acquisition - Newser
Washington speeds psychedelic PTSD work as Silo spotlights program - Stock Titan
Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD - Sahm
Why did SILO stock soar 85% today? - MSN
Levi Strauss, Greenbrier and 3 stocks to watch heading into Tuesday - MSN
SILO Silo Pharma rises 5.57 percent despite reporting a wider than expected Q4 2023 per share loss.Gross Margin - Newser
CMND stock set for biggest intraday gains in over three years — here’s why retail is eyeing further upside - MSN
SILO Price Today: Silo Pharma, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Silo Pharma launches AI subsidiary, advances PTSD drug program By Investing.com - Investing.com India
Silo Pharma Diversifies into AI with Qwikagents Asset Acquisition, Targeting $47-53 Billion Market - citybuzz -
Silo Pharma Inc. posts 76.5% EPS miss with no reported revenueDividend Initiation - Cổng thông tin điện tử tỉnh Tây Ninh
Silo Pharma launches AI subsidiary, advances PTSD drug program - Investing.com
Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents - The Manila Times
A biotech advancing a PTSD drug just bought an AI agent platform - Stock Titan
Silo Pharma Announces Strategic Business Expansion Into Multi-Billion Dollar AI Agent Market With Acquisition of Managed AI Agent Platform, Qwikagents - 富途牛牛
Silo Pharma, Inc. acquired Assets of Qwikagents.ai. - marketscreener.com
Silo Pharma highlights PTSD treatment program amid policy shift By Investing.com - Investing.com India
Silo Pharma highlights PTSD drug program amid policy shift By Investing.com - Investing.com India
Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics - marketscreener.com
Silo Pharma (SILO) Stock Payout Ratio (Momentum Building) 2026-04-20Buy Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Silo Pharma highlights PTSD drug program amid policy shift - Investing.com
Silo Pharma highlights PTSD treatment program amid policy shift - Investing.com
Silo Pharma Positioned to Advance Treatment Targeting PTSD - GlobeNewswire
What's going on in today's after hours session - ChartMill
Silo Pharma (SILO) Stock VWAP Break (+1.18%) 2026-04-18Community Breakout Alerts - Cổng thông tin điện tử tỉnh Lào Cai
Is Silo Pharma (SILO) stock a smart investment (Bullish Momentum) 2026-04-18Viral Momentum Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Form POS AMPost-Effective amendments for registration statement - ADVFN
Silo Pharma (NASDAQ: SILO) registers 5.02M shares underlying warrants; $0.60 strike - Stock Titan
[EFFECT] Silo Pharma, Inc. SEC Filing - Stock Titan
Silo Pharma (SILO) Stock: Why Technology Edge (Institutional Demand) 2026-04-15Delta Trends - UBND thành phố Hải Phòng
Silo Pharma (NASDAQ: SILO) registers 820,911 shares from July 2024 warrants - Stock Titan
Aug Weekly: Is Silo Pharma Inc a strong growth stock2026 Sector Moves & Fast Gaining Stock Reports - baoquankhu1.vn
[POS AM] Silo Pharma, Inc. SEC Filing - Stock Titan
Silo Pharma (SILO) stock soars 47% after European patent win: What you should know - MSN
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Silo Pharma Inc Stock (SILO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Silo Pharma Inc Stock (SILO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Weisblum Eric | Chief Executive Officer |
Nov 20 '25 |
Buy |
0.37 |
1,000 |
370 |
210,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 21 '25 |
Buy |
0.36 |
1,000 |
365 |
211,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 18 '25 |
Buy |
0.40 |
7,500 |
3,025 |
205,432 |
| Weisblum Eric | Chief Executive Officer |
Nov 19 '25 |
Buy |
0.41 |
4,500 |
1,823 |
209,932 |
| Weisblum Eric | Chief Executive Officer |
May 27 '25 |
Buy |
0.43 |
10,000 |
4,329 |
197,932 |
5.78%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):